

WHY IDT AUSTRALIA?

Positioned for clinical stage programs

Is your project too small to be prioritised?
Too complex to be standardised?
Too urgent to wait?

We help complex therapies
get into the clinic - faster

What Makes Us Different



Agile by Design

- Fast onboarding
- Fast decision loops
- Dedicated customer teams



Focused

- Positioned for small complex clinical programs
- Phase I/II execution



Integrated

- Small molecule drug substance through to drug product, on one site
- mRNA/LNP formulation through to sterile fill-finish



Benefits of manufacturing in Australia



Access up to 43.5%
Australian R&D tax
incentive for eligible
programs



Schemes to start
clinical trials
months earlier



Stringent regulatory
standards that are
globally recognised.



Trusted jurisdiction -
secure IP and clinical
supply chain



Small Molecule Drug Substance and Drug Product Execution



Drug Substance



- Complex (HPAPI, cytotoxic, controlled substances)
- Multi-step, hazardous, and scale sensitive chemistry
- Flexible scale: mg to 100s kg
- Rapid transition from development to GMP

Drug Product

Non-Sterile



- Capsules
- Tablets
- Non-sterile liquids

Sterile

- Sterile fill-finish
- Lyophilisation



Integrated Execution



- ✓ Drug substance to drug product on one site
- ✓ Single quality system
- ✓ Reduced tech transfer risk
- ✓ Faster path to clinic

Where we win



- ✓ Small, complex programs not prioritised by large CDMOs
- ✓ Time-critical clinical supply
- ✓ High risk or challenging chemistry
- ✓ Agile scheduling



Book a feasibility assessment with an expert

bd@idtaus.com.au